Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immune-oncology therapies for cancer patients worldwide. Led by a team of enthusiastic scientists, the company has focused its pipeline on removing immunosuppressive factors in the tumor microenvironment, especially by targeting adenosine pathway and myeloid checkpoints. Elpiscience developed several novel molecules with its powerful Bispecific Macrophage Engager (BiME®) that connects and activates macrophages for solid tumor killing without causing cytokine storms.